In light of the beneficial effects of DPP4 inhibition on metabolic disorders, including obesity and diabetes mellitus [43], we propose that DPP4‐GLP‐1/GLP‐1R may be a pivotal regulator of stress‐induced adipose inflammation and dysfunction via the negative modulation of the PI3K/AKT signaling pathway. This evidence concerns the gene AKT1 and metabolic disease.